Alzheimer disease (AD) is the most common cause of dementia and is characterized by the aggregation and accumulation of two proteins in the brain, amyloid-β (Aβ) and tau. Aβ and tau begin to buildup 15-20 years before the clinical onset of AD dementia. Increasing evidence suggests that preventing or decreasing the amount of aggregated forms of both Aβ and tau in the brain can serve as potential disease-modifying treatments for AD.

Original languageEnglish
Pages (from-to)469-471
Number of pages3
JournalClinical pharmacology and therapeutics
Issue number5
StatePublished - Nov 1 2015


Dive into the research topics of 'Current thinking on the mechanistic basis of Alzheimer's and implications for drug development'. Together they form a unique fingerprint.

Cite this